Table 1.
Clinical characteristics and outcomes of patients with anti-NMDA encephalitis.
| No AEDs (14 patients) | Early withdraw (23 patients) | Late withdraw (11 patients) | P1 | P2 | |
|---|---|---|---|---|---|
| Sex (male/female) | 7/7 | 15/8 | 5/6 | 0.474 | 0.458 |
| Age (Ave ± SD) | 6.8 ± 3.26 | 21.0 ± 16.19 | 21.4 ± 11.89 | 0.004 | 0.935 |
| Seizure frequency | 0.038 | 0.359 | |||
| None | 4 | 5 | 2 | ||
| Once | 7 | 2 | 3 | ||
| Repeated | 3 | 16 | 6 | ||
| Seizure with focal characters | 0 | 2 | 0 | 0.322 | 0.313 |
| Status epilepticus(Yes/No) | 0/14 | 6/17 | 5/6 | 0.024 | 0.259 |
| Antibody titer | 0.129 | 0.727 | |||
| 1:10 | 6 | 3 | 1 | ||
| 1:32 | 7 | 19 | 10 | ||
| 1:100 | 1 | 1 | 0 | ||
| MRI abnormalities | 0.400 | 0.329 | |||
| None | 4 | 6 | 6 | ||
| White matter | 3 | 3 | 1 | ||
| Cortex | 3 | 2 | 0 | ||
| Anti-epileptic drugs | – | 0.934 | |||
| 1 kind | – | 16 | 7 | ||
| 2 kinds | – | 5 | 3 | ||
| 3 or more kinds | – | 2 | 1 | ||
| Followed up | |||||
| Median duration (months) | 20 (14–36) | 36 (15–50) | 32 (17–62) | ||
| Relapse | – | 2/21 | 0/11 | – | 0.313 |
| mRS score (≤1/>1) | 12/2 | 22/1 | 9/2 | 0.398 | 0.239 |
AED, Antiepileptic drug. P1, P-value among No AED, Early withdraw, and late withdraw group. P2, P-value between Early withdraw, and late withdraw group.